BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 5, 2025
See today's BioWorld
Home
» FDA accepts Beigene’s first filing outside China; BLA seeks nod for anti-PD-1 tislelizumab
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA accepts Beigene’s first filing outside China; BLA seeks nod for anti-PD-1 tislelizumab
Sep. 16, 2021
By
Doris Yu
No Comments
The FDA has accepted for review Novartis AG and Beigene Ltd.’s BLA filing for the anti-PD-1 monoclonal antibody tislelizumab.
BioWorld
Regulatory
Cancer
China
BLA
FDA
